戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  avoid harm when treating patients with oral terbinafine.
2 y overall for the azoles, echinocandins, and terbinafine.
3 ytotoxic effect of Transfersome(R)-delivered terbinafine.
4 ergosterol pathway-targeting antifungal drug terbinafine.
5 ars to potentiate the antifungal activity of terbinafine.
6 nazole and less active than itraconazole and terbinafine.
7 fluconazole, griseofulvin, itraconazole, and terbinafine.
8  anidulafungin, caspofungin, micafungin, and terbinafine.
9 ants to the sterol synthesis inhibiting drug terbinafine.
10 L; ketoconazole, bimodal, no ECV determined; terbinafine, 0.25 ug/mL; flucytosine, rejected; and amph
11 e.g., untreated control, treated groups with terbinafine 1%, niosome, PL gel 1%, and PL niosomal gel
12 aked terbinafine, and commercially available terbinafine (1%) spray.
13 ween both methods were as follows: 100% with terbinafine, 97.8% with ciclopirox, and 89.1% with voric
14 ratio = 0.44) compared with patients without terbinafine administration.
15 ntified a total of 185 patients who received terbinafine after their CRC diagnosis and found that the
16                                              Terbinafine also demonstrated statistical superiority wh
17 ure to further understand the specificity of terbinafine, an approved agent targeting fungal SQLE, an
18 re whether reversing the fungal dysbiosis by terbinafine, an approved antifungal drug, might inhibit
19 ts had comparable effects on the activity of terbinafine, an inhibitor of squalene epoxidase within t
20 ubrum strains known to have elevated MICs to terbinafine and five Trichophyton mentagrophytes strains
21  for earlier isolates that were resistant to terbinafine and identified 3 additional T. indotineae is
22 llowed by long-term combination therapy with terbinafine and ketoconazole.
23 gainst the Ochroconis isolates revealed that terbinafine and micafungin were the most active drugs.
24 8-fold and 60-fold lower than those of naked terbinafine and terbinafine spray, respectively.
25 es for T. rubrum and E. floccosum than naked terbinafine and terbinafine spray.
26 ith those of the Transfersome vehicle, naked terbinafine, and commercially available terbinafine (1%)
27  the mean MICs of fluconazole, itraconazole, terbinafine, and griseofulvin were 2.07 +/- 0.29, 0.13 +
28 e, griseofulvin, itraconazole, posaconazole, terbinafine, and voriconazole.
29 e, griseofulvin, itraconazole, posaconazole, terbinafine, and voriconazole.
30 ally relevant liver toxic effects related to terbinafine at a prevalence of 75% was between $18.2 mil
31                                Collectively, terbinafine can inhibit CRC by reversing fungal dysbiosi
32                                 We show that terbinafine causes local collapse of the fungal endoplas
33 ifungal susceptibilities of dermatophytes to terbinafine, ciclopirox, and voriconazole in comparison
34 o 0.25 mug/ml, and 0.008 to 0.025 mug/ml for terbinafine, ciclopirox, and voriconazole, respectively.
35 tiple mouse models of CRC, administration of terbinafine decreased the fungal load, the fungus-induce
36                             Mechanistically, terbinafine directly impaired tumor cell proliferation b
37                            The triazoles and terbinafine exhibited low MICs against all Exophiala iso
38                                              Terbinafine, fluconazole, and amorolfine inhibit fungal
39 , posaconazole, isavuconazole, ketoconazole, terbinafine, flucytosine, and amphotericin B.
40 e results show that empirical treatment with terbinafine for patients with suspected onychomycosis is
41 ity of which demonstrated low MIC values for terbinafine (geometric mean [GM] and modal MIC, 0.031 mu
42                           In contrast to the terbinafine group, which demonstrated no efficacy (P < 0
43             Itraconazole, isavuconazole, and terbinafine had higher MIC values against Scedosporium s
44 d cure outcome, butenafine hydrochloride and terbinafine hydrochloride were significantly more effica
45 ed dosage form (liquid spray) of 15 mg/ml of terbinafine in Transfersome that has been developed to d
46 t TDT 067 (a topical formulation of 15 mg/ml terbinafine in Transfersome(R) vesicles) has a much more
47 synthesis genes and increased sensitivity to terbinafine, indicating a sterol-responsive role for SRE
48 or the treatment of tinea capitis, including terbinafine, itraconazole, and fluconazole in this era o
49 of dermatophytes were compared with those of terbinafine, itraconazole, ketoconazole, griseofulvin, a
50 .6% of the isolates tested were resistant to terbinafine (MIC >= 0.5 mug/mL), including 21 T. rubrum
51                   Butenafine, naftifine, and terbinafine might be the best strategies for maintaining
52         Relative to the other agents tested, terbinafine possessed the highest antifungal activity ag
53  that cause nail infection than conventional terbinafine preparations.
54 dotineae isolates have exhibited significant terbinafine resistance due to mutations in the Squalene
55               These results demonstrate that terbinafine resistance in dermatophytes was relatively c
56  and to provide the structural insights into terbinafine-resistant mutants encountered in the clinic.
57 ved isolates, we identified the emergence of terbinafine-resistant T. concentricum microbiologically
58 vi) Treatment of S. cerevisiae with azole or terbinafine resulted in transcriptional upregulation of
59 ld lower than those of naked terbinafine and terbinafine spray, respectively.
60  and E. floccosum than naked terbinafine and terbinafine spray.
61 ase gene mutations associated with decreased terbinafine susceptibility have been identified in Unite
62 wo nanoparticles, sorafenib-glycyrrhizin and terbinafine-taurocholic acid both ex vivo and in vivo.
63 ection using the sterol synthesis inhibitors terbinafine (TBF, targeting squalene epoxidase) and itra
64                           Resistance to oral terbinafine, the most commonly used antifungal to treat
65 f 75%, per-patient cost savings of empirical terbinafine therapy without confirmatory testing was $47
66 ansfersomes deliver the lipophilic fungicide Terbinafine to the fungal cell wall, (b) the membrane so
67 nsfersome that has been developed to deliver terbinafine to the nail bed to treat onychomycosis.
68 e role of Ca2+-regulated signalling in azole/terbinafine tolerance is proposed.
69 n vitro activity of amphotericin B (AMB) and terbinafine (TRB) and of the echinocandins against Penic
70 as used to study the in vitro interaction of terbinafine (TRB) with fluconazole (FLU), itraconazole (
71 microbiota transplantation from mice without terbinafine treatment reversed MDSC infiltration and par
72 -line therapy, but successful treatment with terbinafine, voriconazole, and posaconazole has been rep
73 mic reticulum, which was more efficient when terbinafine was delivered in Transfersome(R) vesicles (T
74 d droplets after entry into the cell and the terbinafine was released from their interior.
75 e commonly used antifungals itraconazole and terbinafine were 0.5 and 0.25 ug/mL, respectively.
76 activity in vitro compared with conventional terbinafine, which is a water-insoluble fungicide.
77 t activity were caspofungin, micafungin, and terbinafine, while amphotericin B showed the least activ
78  the salvage therapeutics amphotericin B and terbinafine without significantly affecting pathogenicit